Noora (vaccine)
From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
|
Timeline 2019 2020
2021
2022 |
Locations By country and territory
By conveyance
|
International response
National responses |
Medical response
Vaccines
Vaccine candidates
|
Impacts
Society
|
COVID-19 portal |
|
Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in Iran.[1][2]
Medical uses[]
It requiring three doses given by intramuscular injection on days 0, 21 and 35.[3]
Pharmacology[]
Noora is a recombinant RBD protein subunit vaccine.[3]
Manufacturing[]
Up to 8 December 2021, 5 millions doses have been produced.[4]
Clinical trials[]
Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
---|---|---|---|---|---|---|---|
Total | Vaccine | Placebo | |||||
I | IRCT20210620051639N1 | 25 June 2021 | 70 | 30 (80 µg)
30 (120 µg) |
10 (placebo) | 18–50 years | [3] |
II | IRCT20210620051639N2 | 10 October 2021 | 300 | 240 | 60 | 18–40 years | [5] |
III | IRCT20210620051639N3 | 23 December 2021 | 10000 | >18 years | [6] |
See also[]
- Pharmaceuticals in Iran
- COVID-19 pandemic in Iran
- COVID-19 vaccine clinical research
References[]
- ^ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
- ^ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. Retrieved 30 August 2021.
- ^ a b c "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
- ^ "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim". خبرگزاری تسنیم | Tasnim (in Persian). Retrieved 8 December 2021.
- ^ "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population". en.irct.ir. Retrieved 27 November 2021.
- ^ "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". en.irct.ir. Retrieved 23 December 2021.
Scholia has a profile for Noora (Q108542111). |
Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Development |
| ||||||||||
Classes |
| ||||||||||
Administration |
| ||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers |
| ||||||||||
Controversy |
| ||||||||||
Related |
| ||||||||||
|
COVID-19 pandemic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Portals:
Medicine
Viruses
COVID-19
This article about COVID-19 vaccines is a stub. You can help Wikipedia by . |
- v
- t
This article about vaccines or vaccination is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Clinical trials
- Iranian COVID-19 vaccines
- Science and technology in Iran
- Protein subunit vaccines
- COVID-19 vaccine stubs
- Vaccine stubs
Hidden categories:
- CS1 Persian-language sources (fa)
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from August 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Articles containing Persian-language text
- All stub articles